In the News
U.S. antibiotic resistance rates for H. pylori appear high
A systematic review and meta-analysis of resistance patterns of Helicobacter pylori strains found that resistance to metronidazole, levofloxacin, and clarithromycin exceeds 30%.
Review examines drugs, lifestyle treatments for NAFLD
The umbrella review included 27 meta-analyses of randomized controlled trials examining the effectiveness of pharmacological interventions and lifestyle modifications, including diet and exercise, for patients with nonalcoholic fatty liver disease (NAFLD).
Patient navigation associated with increased care, treatment in hepatitis C
A pre-post study in a safety-net health system found higher odds of linkage to care and direct-acting antiviral treatment in older adults who received patient navigation rather than usual care.
MKSAP Quiz: Next steps after a GI bleed
This month's quiz asks readers to determine the most appropriate next step in management for a 40-year-old patient who was discharged six weeks ago after hospitalization for upper GI bleeding and whose most recent upper endoscopy showed a healing Mallory-Weiss tear.
Spotlight on NAFLD outcomes
Recent studies found associations between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease, sarcopenia, and mortality.
Manage meds to treat GI bleeding before, after endoscopy
Care of inpatients with GI bleeding is complicated and multidisciplinary, but hospitalists can contribute by starting and stopping the right drugs, according to conference coverage from Internal Medicine Meeting 2022.
Care of the patient after metabolic and bariatric surgery
An In the Clinic article reviewed key issues that internists should be aware of to help support patients' health in the short and long term after weight loss surgery.
Case reports published on gastroenterology topics
Reports on gastric hyperplastic polyps and upper GI bleeding, rectal ulceration after radiation therapy, and primary epiploic appendagitis were published this month.
FDA approves first treatment for eosinophilic esophagitis
The monoclonal antibody is indicated to treat the chronic immune disorder in adults and pediatric patients ages 12 years and older who weigh at least 40 kg.